Modified mycobacterium bovis vaccines

NZ797622BActive Publication Date: 2026-07-28VALO THERAPEUTICS OY
0 Cites 0 Cited by

Patent Information

Application Number
NZ797622
Authority / Receiving Office
NZ · NZ
Patent Type
Patents
Current Assignee / Owner
Priority Date
2021-07-08
Filing Date
2021-08-27
Publication Date
2026-07-28
Estimated Expiration
2041-08-27

AI Technical Summary

Technical Problem

Current BCG vaccines have variable efficacy in preventing tuberculosis, especially in adults and HIV-infected individuals, and lack convincing evidence for protective effects against tuberculosis progression, while also facing challenges in cancer treatment due to limited immune response modulation.

Method used

Development of a modified Mycobacterium bovis vaccine, PeptiBAC, coated with peptide antigens using a polylysine or poly-arginine linker to enhance immune response, specifically targeting infectious diseases like tuberculosis and cancer by eliciting a strong immune reaction through intradermal or intranasal administration.

Benefits of technology

PeptiBAC induces robust immune responses, including tumor-specific CD8+ T cell activation and enhanced effector functions, improving treatment outcomes for infectious diseases and cancer by increasing the effectiveness of immune checkpoint inhibitor therapies.

✦ Generated by Eureka AI based on patent content.
Patent Text Reader

Abstract

The invention concerns a modified bacteria; a pharmaceutical composition comprising same; and a method of preventing or treating disease particularly, but not exclusively, cancer or an infectious disease using same. The modified bacteria is a Bacillus Calmette-Guerin (BCG) strain coated with antigenic peptides via poly-lysine or poly-arginine linkers. They elicit T cell responses and are useful for preventing, treating, or vaccinating against diseases, including cancer.
Need to check novelty before this filing date? Find Prior Art